Tower Research Capital LLC (TRC) - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 65 filers reported holding PROQR THRAPEUTICS N V in Q1 2021. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q1 2023$30
+50.0%
14,132
+164.8%
0.00%0.0%
Q4 2022$20
-99.8%
5,336
-59.8%
0.00%
Q3 2022$10,000
-28.6%
13,274
-26.9%
0.00%
Q2 2022$14,000
+600.0%
18,157
+702.7%
0.00%
Q1 2022$2,000
-87.5%
2,262
+17.0%
0.00%
Q4 2021$16,000
-84.5%
1,934
-87.6%
0.00%
-100.0%
Q1 2021$103,000
+10200.0%
15,646
+7723.0%
0.00%
Q4 2020$1,000
-97.7%
200
-97.8%
0.00%
Q3 2020$43,000
+437.5%
8,959
+578.7%
0.00%
Q2 2020$8,000
+300.0%
1,320
+328.6%
0.00%
Q1 2020$2,000
-95.0%
308
-92.4%
0.00%
-100.0%
Q4 2019$40,000
-49.4%
4,073
-52.9%
0.00%
-40.0%
Q2 2019$79,000
+777.8%
8,647
+1446.9%
0.01%
+400.0%
Q4 2018$9,000
+200.0%
559
+282.9%
0.00%
Q3 2018$3,000
-40.0%
146
-90.8%
0.00%
Q1 2018$5,000
-28.6%
1,590
-30.1%
0.00%
-100.0%
Q4 2017$7,000
-50.0%
2,275
-22.6%
0.00%0.0%
Q3 2017$14,000
+180.0%
2,939
+274.4%
0.00%
Q3 2016$5,000
+25.0%
7850.0%0.00%
Q2 2016$4,000
+33.3%
785
+25.4%
0.00%
Q1 2016$3,000
+200.0%
626
+464.0%
0.00%
Q4 2015$1,000
-92.3%
111
-87.7%
0.00%
-100.0%
Q3 2015$13,000
+62.5%
902
+88.7%
0.00%0.0%
Q2 2015$8,000
+60.0%
478
+123.4%
0.00%0.0%
Q1 2015$5,0002140.00%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q1 2021
NameSharesValueWeighting ↓
M28 Capital Management LP 1,910,600$2,483,7802.85%
Privium Fund Management B.V. 5,344,446$6,947,7802.07%
DAFNA Capital Management LLC 940,582$1,222,7570.38%
Monaco Asset Management SAM 377,517$490,7720.15%
EcoR1 Capital, LLC 2,980,016$3,874,0210.13%
Ikarian Capital, LLC 472,625$614,4120.07%
FRANKLIN STREET ADVISORS INC /NC 150,000$1950.02%
ADAGE CAPITAL PARTNERS GP, L.L.C. 3,625,467$4,713,1070.01%
GSA CAPITAL PARTNERS LLP 74,084$960.01%
UBS OCONNOR LLC 189,328$246,1260.01%
View complete list of PROQR THRAPEUTICS N V shareholders